These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

801 related items for PubMed ID: 29247711

  • 1. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY, Zhang M, Cong Q, Zhang MX, Zhang MY, Lu YY, Xu CJ.
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [Abstract] [Full Text] [Related]

  • 2. Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism.
    Zhang M, Liu Q, Zhang M, Cao C, Liu X, Zhang M, Li G, Xu C, Zhang X.
    J Nanobiotechnology; 2020 Nov 07; 18(1):161. PubMed ID: 33160373
    [Abstract] [Full Text] [Related]

  • 3. Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance.
    Yu L, Gu C, Zhong D, Shi L, Kong Y, Zhou Z, Liu S.
    Cancer Lett; 2014 Dec 01; 355(1):34-45. PubMed ID: 25236911
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
    He R, Liu H.
    Gene; 2020 Jul 15; 747():144553. PubMed ID: 32165307
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
    Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC, Lu Z.
    Cell Death Dis; 2015 Aug 06; 6(8):e1836. PubMed ID: 26247722
    [Abstract] [Full Text] [Related]

  • 8. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK, Wong OG, Wong ES, Chan KK, Ip PP, Tse KY, Cheung AN.
    Int J Cancer; 2018 Sep 15; 143(6):1456-1469. PubMed ID: 29663364
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. PGC1α Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway.
    Li Y, Kang J, Fu J, Luo H, Liu Y, Li Y, Sun L.
    Int J Mol Sci; 2021 Mar 03; 22(5):. PubMed ID: 33802591
    [Abstract] [Full Text] [Related]

  • 12. Molecular imaging of the kinetics of hyperactivated ERK1/2-mediated autophagy during acquirement of chemoresistance.
    Bishnu A, Phadte P, Dhadve A, Sakpal A, Rekhi B, Ray P.
    Cell Death Dis; 2021 Feb 08; 12(2):161. PubMed ID: 33558461
    [Abstract] [Full Text] [Related]

  • 13. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H, Fang L, Jiang J, Kuang Y, Wang B, Shang X, Han P, Li Y, Liu M, Zhang Z, Li P.
    Cell Death Dis; 2018 Oct 30; 9(11):1103. PubMed ID: 30375398
    [Abstract] [Full Text] [Related]

  • 14. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells.
    Sun H, Wang H, Wang X, Aoki Y, Wang X, Yang Y, Cheng X, Wang Z, Wang X.
    Theranostics; 2020 Oct 30; 10(15):6928-6945. PubMed ID: 32550913
    [Abstract] [Full Text] [Related]

  • 15. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF, Chou CY.
    Oncotarget; 2015 Feb 10; 6(4):2349-65. PubMed ID: 25537512
    [Abstract] [Full Text] [Related]

  • 16. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
    Ma H, Li Y, Wang X, Wu H, Qi G, Li R, Yang N, Gao M, Yan S, Yuan C, Kong B.
    Cell Death Dis; 2019 Feb 18; 10(3):166. PubMed ID: 30778048
    [Abstract] [Full Text] [Related]

  • 17. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
    Zhang M, Cong Q, Zhang XY, Zhang MX, Lu YY, Xu CJ.
    J Cell Physiol; 2019 May 18; 234(5):6361-6370. PubMed ID: 30229902
    [Abstract] [Full Text] [Related]

  • 18. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
    Zhang X, Qi Z, Yin H, Yang G.
    Theranostics; 2019 May 18; 9(4):1096-1114. PubMed ID: 30867818
    [Abstract] [Full Text] [Related]

  • 19. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
    Wang Z, Liu S, Ding K, Ding S, Li C, Lu J, Gao D, Zhang T, Bi D.
    Tumour Biol; 2016 Nov 18; 37(11):15133-15143. PubMed ID: 27677286
    [Abstract] [Full Text] [Related]

  • 20. Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer.
    Zhou F, Yang X, Zhao H, Liu Y, Feng Y, An R, Lv X, Li J, Chen B.
    Theranostics; 2018 Nov 18; 8(19):5200-5212. PubMed ID: 30555541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.